Find out more about Peter Grant's experience
Peter Grant's highlights
Peter Grant's selected work
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recur..
Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with..
Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk..
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone..
Displaying the most recent project by Peter Grant.
Displaying the 12 most recent scholarly works by Peter Grant.
Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?
Vanessa L Beesley, Tanya L Ross, Nina Renhua Na, Tharani Sivakumaran, George Au-Yeung, Christina M Nagle, Anna deFazio, Peter Grant, Andreas Obermair, Michael Friedlander, Penelope Webb
Conference Proceedings | 2019 | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Monica Tang, Rachel L O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander
Journal article | 2019 | Gynecologic Oncology
OBJECTIVE: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borde..
Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.
Tharani Sivakumaran, Linda R Mileshkin, Peter T Grant, Michael Friedlander, Penelope M Webb, George Au-Yeung
Conference Proceedings | 2018 | Journal of Clinical Oncology
Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer
YC Lee, M Bressel, P Grant, P Russell, C Smith, S Picken, S Camm, BE Kiely, RL Milne, SA McLachlan, M Hickey, ML Friedlander, JL Hopper, KA Phillips
Journal article | 2017 | Familial Cancer
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer
Anthony Bonaventura, Rachel L O'Connell, Cristina Mapagu, Philip J Beale, Orla M McNally, Linda R Mileshkin, Peter T Grant, Alison M Hadley, Jeffery CH Goh, Katrin M Sjoquist, Julie Martyn, Anna DeFazio, James Scurry, Michael L Friedlander
Journal article | 2017 | International Journal of Gynecological Cancer
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.
Paul Lr Mitchell, Michael A Quinn, Peter T Grant, David G Allen, Thomas W Jobling, Shane C White, Anne Zhao, Vaios Karanikas, Hilary Vaughan, Geoffrey Pietersz, Ian Fc McKenzie, Sharron E Gargosky, Bruce E Loveland
Journal article | 2014 | Journal for ImmunoTherapy of Cancer
BACKGROUND: Mucin 1 antigen, highly expressed by epithelial ovarian cancer (EOC), is a potential target for immunotherapy. A previ..
Benign endocervical cystic glandular change mimicking minimal deviation adenocarcinoma of the cervix on magnetic resonance imaging: A case report
M Bardsley, S Pather, D Neesham, A Dobrotwir, B Brown, M Quinn, P Grant
Journal article | 2004 | Australian and New Zealand Journal of Obstetrics and Gynaecology
Obstetrics And Gynaecology Royal Women'S Hospital/Mercy